2,976 reports of this reaction
2.4% of all RUXOLITINIB reports
#4 most reported adverse reaction
ANAEMIA is the #4 most commonly reported adverse reaction for RUXOLITINIB, manufactured by Incyte Corporation. There are 2,976 FDA adverse event reports linking RUXOLITINIB to ANAEMIA. This represents approximately 2.4% of all 126,373 adverse event reports for this drug.
RUXOLITINIB has an overall safety score of 85 out of 100. Patients taking RUXOLITINIB who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is a less commonly reported adverse event for RUXOLITINIB, but still significant enough to appear in the safety profile.
In addition to anaemia, the following adverse reactions have been reported for RUXOLITINIB:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 2,976 FDA reports for RUXOLITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 2.4% of all adverse event reports for RUXOLITINIB, making it a notable side effect.
If you experience anaemia while taking RUXOLITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.